
- /
- Supported exchanges
- / F
- / CU2.F
Cerus Corporation (CU2 F) stock market data APIs
Cerus Corporation Financial Data Overview
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Cerus Corporation data using free add-ons & libraries
Get Cerus Corporation Fundamental Data
Cerus Corporation Fundamental data includes:
- Net Revenue: 176 M
- EBITDA: -9 630 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-03
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cerus Corporation News

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update
Preliminary Fourth Quarter and Full-Year 2023 Product Revenues of $46.8 million and $156.4 million, respectively 2024 Product Revenues expected to be between $172-$175 million, reflecting 10%-12% gro...


Shareholders in Cerus (NASDAQ:CERS) are in the red if they invested three years ago
It is a pleasure to report that the Cerus Corporation (NASDAQ:CERS) is up 39% in the last quarter. But that doesn't change the fact that the returns over the last three years have been stomach churnin...

Positive week for Cerus Corporation (NASDAQ:CERS) institutional investors who lost 54% over the past year
Key Insights Significantly high institutional ownership implies Cerus' stock price is sensitive to their trading actions A total of 9 investors have a majority stake in the company with 51% ownership...

Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Call Transcript November 2, 2023 Cerus Corporation beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.05. Operator: Good day ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.